A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Imidazolopiperazine KAF156 To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers

Gelijkaardige items

• A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
  door: Leong, F. Joel, et al.
  Gepubliceerd in: (2014)
• A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers
  door: Leong, Joel, et al.
  Gepubliceerd in: (2014)
• Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria
  door: White, Nicholas J., et al.
  Gepubliceerd in: (2016)
• A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study To Assess the Safety and Tolerability of LFF571 in Healthy Volunteers
  door: Ting, Lillian S. L., et al.
  Gepubliceerd in: (2012)
• A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine
  door: Leong, F. Joel, et al.
  Gepubliceerd in: (2018)